anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In a randomized, multicenter, double-blind, parallel group study, a single 10 mg subcutaneous dose of SUSTOL was compared to a single 0.25 mg intravenous dose of palonosetron hydrochloride in cancer patients administered moderately emetogenic (MEC) or anthracycline plus cyclophosphamide (AC) combination chemotherapy. SUSTOL or palonosetron hydrochloride was administered 30 minutes prior to chemotherapy on Day 1. Patients also received either 8 or 20 mg intravenous dexamethasone on Day 1 depending on chemotherapy regimen. Patients who received 20 mg of intravenous dexamethasone also received oral dexamethasone 8 mg twice daily on Days 2, 3, and 4.

In this study of 733 patients (371 in the SUSTOL 10 mg arm and 362 in the palonosetron arm), 79% of patients were female and 63% were Caucasian. The mean age was 57 years (range 22 to 91 years), 55% received MEC and 45% received AC combination chemotherapy regimens. The most common MEC regimens were carboplatin/paclitaxel (31%).

The primary endpoints were proportion of patients with complete response (CR) [defined as no emetic episodes (vomiting or retching) and no use of rescue medication] during the acute phase (0 to 24 hours) and the delayed phase (>24 to 120 hours) following the administration of chemotherapy in Cycle 1. The study design allowed for assessment of non-inferiority of SUSTOL to palonosetron hydrochloride in the acute and delayed phase of MEC and of AC combination chemotherapy.

Non-inferiority of SUSTOL to palonosetron hydrochloride was demonstrated in the acute and delayed phases of MEC and of AC combination chemotherapy [Table 4].
Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage.In pediatric dentistry, the injection of local anesthesia is the most common cause of fear and expected to be painful.So, an effective pain control significantly contributes to an optimal dental treatment in pediatric dentistry.Proper pain prevention may enhance the child's cooperation by building dentist-child trust and reducing fear and/or anxiety during the current or future visit(s). The purpose of this study is to compare the efficacy of three different approaches of LA administration(Warm\[37°C\] LA, Buffered LA, and BUZZY device) on pain perception to young children ( 6-12 years old) using sound -eye -motor and Wong-Baker FPR scales. This study will be conducted on 80 children aged between 6-12 years from pediatric dental clinic, Faculty of Dentistry, Mansoura University. Children will be divided to 4 equal groups, 20 children each. Three experimental groups, and a (control group) . The 4 groups will be randomly allocated for each technique using block technique of simple random sampling .Randomized block designs are constructed to reduce noise or variance in the data.

Every block will include the equal number of the four groups (three experimental and one control).
The invention provides a method for treating ulcerative colitis by using a coptis-dark plum-monkshood-ginger decoction. The method comprises (1) treatment via the coptis-dark plum-monkshood-ginger decoction, and (2) moxibustion. A prescription for the coptis-dark plum-monkshood-ginger decoction comprises 6 g of coptis, 15 g of dark plum, 9 g of prepared monkshood slice, 10 g of dried ginger, 15 g of wrinkled giant hyssop, 8 g of cardamom, 20 g of stir-fried white peony root, 15 g of Radix Codonopsis, 10 g of phellodendron, 8 g of cassia bark, 9 g of Chinese angelica, 10 g of Psoralea corylifolia and 12 g of baked terminalia fruit. For people with dampness and heat in the intestines, 10 g of ash bark and 20 g of garden burnet are added into the prescription; for people with weakness of the spleen and the stomach, 15 g of bighead atractylodes rhizome and 12 g of medicated leaven are added into the prescription; for people with incoordination between the liver and the spleen, 10 g of divaricate saposhnikovia root and 9 g of dried orange peel are added into the prescription; for people with yang deficiency in the spleen and the kidney, 6 g of evodia fruit and 3 g of Chinese prickly ash are added into the prescription; for people with deficiency of yin and blood, Radix Codonopsis in the prescription is changed into 10 g of American ginseng (which is decocted and taken separately), and 15 g of asparagi radix is added into the prescription; and for people with stasis of blood in the intestines and channels, 9 g of cattail pollen and 15 g of flying squirrel feces are added into the prescription. One dosage of the precipitation is taken each day and decocted with 450 mL of warm water three times, each time lasting for 15 to 20 min; 150 ml of decoction is left each time; and the decoction is orally taken in half an hour after breakfast, lunch and dinner, respectively. According to moxibustion, moxa sticks are employed for circling moxibustion of the acupoints of Sanyinjiao, Diji and Yinlingquan of spleen channels of foot-taiyin at two sides once a day, wherein each circling moxibustion lasts for 10 to 15 min until skin around the acupoints is hematose and red.
Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
Advances in cancer therapeutics have improved patient survival rates. However, cancer survivors may suffer from adverse events either at the time of therapy or later in life. Cardiovascular diseases (CVD) represent a clinically important, but mechanistically understudied complication, which interfere with the continuation of best-possible care, induce life-threatening risks, and/or lead to long-term morbidity. These concerns are exacerbated by the fact that targeted therapies and immunotherapies are frequently combined with radiotherapy, which induces durable inflammatory and immunogenic responses, thereby providing a fertile ground for the development of CVDs. Stressed and dying irradiated cells produce 'danger' signals including, but not limited to, major histocompatibility complexes, cell-adhesion molecules, proinflammatory cytokines, and damage-associated molecular patterns. These factors activate intercellular signaling pathways which have potentially detrimental effects on the heart tissue homeostasis. Herein, we present the clinical crosstalk between cancer and heart diseases, describe how it is potentiated by cancer therapies, and highlight the multifactorial nature of the underlying mechanisms. We particularly focus on radiotherapy, as a case known to often induce cardiovascular complications even decades after treatment. We provide evidence that the secretome of irradiated tumors entails factors that exert systemic, remote effects on the cardiac tissue, potentially predisposing it to CVDs. We suggest how diverse disciplines can utilize pertinent state-of-the-art methods in feasible experimental workflows, to shed light on the molecular mechanisms of radiotherapy-related cardiotoxicity at the organismal level and untangle the desirable immunogenic properties of cancer therapies from their detrimental effects on heart tissue. Results of such highly collaborative efforts hold promise to be translated to next-generation regimens that maximize tumor control, minimize cardiovascular complications, and support quality of life in cancer survivors.
Propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
Premature birth or complications during labor can cause temporary disruption of cerebral blood flow, often followed by long-term disturbances in brain development called hypoxic-ischemic (HI) encephalopathy. Diffuse damage to the white matter is the most frequently detected pathology in this condition. We hypothesized that oligodendrocyte progenitor cell (OPC) differentiation disturbed by mild neonatal asphyxia may affect the viability, maturation, and physiological functioning of oligodendrocytes. To address this issue, we studied the effect of temporal HI in the in vivo model in P7 rats with magnetic resonance imaging (MRI), microscopy techniques and biochemical analyses. Moreover, we recreated the injury in vitro performing the procedure of oxygen-glucose deprivation on rat neonatal OPCs to determine its effect on cell viability, proliferation, and differentiation. In the in vivo model, MRI evaluation revealed changes in the volume of different brain regions, as well as changes in the directional diffusivity of water in brain tissue that may suggest pathological changes to myelinated neuronal fibers. Hypomyelination was observed in the cortex, striatum, and CA3 region of the hippocampus. Severe changes to myelin ultrastructure were observed, including delamination of myelin sheets. Interestingly, shortly after the injury, an increase in oligodendrocyte proliferation was observed, followed by an overproduction of myelin proteins 4 weeks after HI. Results verified with the in vitro model indicate, that in the first days after damage, OPCs do not show reduced viability, intensively proliferate, and overexpress myelin proteins and oligodendrocyte-specific transcription factors. In conclusion, despite the increase in oligodendrocyte proliferation and myelin protein expression after HI, the production of functional myelin sheaths in brain tissue is impaired. Presented study provides a detailed description of oligodendrocyte pathophysiology developed in an effect of HI injury, resulting in an altered CNS myelination. The described models may serve as useful tools for searching and testing effective of effective myelination-supporting therapies for HI injuries.
The invention discloses a health product for improving nutritional anemia prepared from plant extracts and ox blood extracts. Preferably, the weight ratio of the ox blood extracts to the plant extracts is 1:1. Animal tests prove that the health product can obviously increase the body weight of a rat suffering from iron deficiency anemia, increase a haemoglobin content of the rat suffering from iron deficiency anemia and decrease free protoporphyrins in red blood cells. Tests on acute toxicity and undue toxicity show that the toxic reaction dosage of the health product is obviously increased. The invention also provides a method for preparing the health product. The preparation method has the advantages of simple extraction process, no chemical pollution, no generation of industrial 'three wastes' and wide industrial application prospect.
GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
BACKGROUND: Fingertip pulse oximeters are widely available, inexpensive, and commonly used to make clinical decisions in many settings. Device performance is largely unregulated and poorly characterised, especially in people with dark skin pigmentation.
METHODS: Eleven popular fingertip pulse oximeters were evaluated using the US Food and Drug Administration (FDA) Guidance (2013) and International Organization for Standardization Standards (ISO, 2017) in 34 healthy humans with diverse skin pigmentation utilising a controlled desaturation study with arterial oxygen saturation (SaO 2) plateaus between 70% and 100%. Skin pigmentation was assessed subjectively using a perceived Fitzpatrick Scale (pFP) and objectively using the individual typology angle (ITA) via spectrophotometry at nine anatomical sites.
FINDINGS: Five of 11 devices had a root mean square error (ARMS) > 3%, falling outside the acceptable FDA performance range. Nine devices demonstrated worse performance in participants in the darkest skin pigmentation category compared with those in the lightest category. A commonly used subjective skin colour scale frequently miscategorised participants as being darkly pigmented when compared to objective quantification of skin pigment by ITA.
INTERPRETATION: Fingertip pulse oximeters have variable performance, frequently not meeting regulatory requirements for clinical use, and occasionally contradicting claims made by manufacturers. Most devices showed a trend toward worse performance in participants with darker skin pigment. Regulatory standards do not adequately account for the impact of skin pigmentation on device performance. We recommend that the pFP and other non-standardised subjective skin colour scales should no longer be used for defining diversity of skin pigmentation. Reliable methods for characterising skin pigmentation to improve diversity and equitable performance of pulse oximeters are needed.
FUNDING: This study was conducted as part of the Open Oximetry Project funded by the Gordon and Betty Moore Foundation, Patrick J McGovern Foundation, and Robert Wood Johnson Foundation. The UCSF Hypoxia Research Laboratory receives funding from multiple industry sponsors to test the sponsors' devices for the purposes of product development and regulatory performance testing. Data in this paper do not include sponsor's study devices. All data were collected from devices procured by the Hypoxia Research Laboratory for the purposes of independent research. No company provided any direct funding for this study, participated in study design or analysis, or was involved in analysing data or writing the manuscript. None of the authors own stock or equity interests in any pulse oximeter companies. Dr Ellis Monk's time utilised for data analysis, reviewing and editing was funded by grant number: DP2MH132941.
In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
PURPOSE:The titled cosmetic, obtained by granulating a fat or oil, e.g. waxy ester or a hydrocarbon, having a specific melting point with another powdery base, and compression molding the resultant granule, and having good shape retaining property and feedling of use. CONSTITUTION:A stick-like powdery cosmetic containing 1-20wt%, preferably 5-15wt%, fat or oil, e.g. microcrystalline wax, carnauba wax or rice wax, having a melting point of 60-100 deg.C. The resultant cosmetic will not damage or collapse the stick thereof in use, and has improved spreading and adhesiveness to the skin. The granulation and compression are carried out by mixing a fat or oil with a powdery base at the melting temperature or below, adhering the fat or oil to the base, and heating the resultant mixture at a temperature 10-30 deg.C higher than the melting point of the fat or oil, finely pulverizing the heated mixture under cooling to give a particle size <=50mu, and compression molding the resultant fine powder.
Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+- dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+. Oxytocin has specific receptors in the myometrium and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. The response to a given dose of oxytocin is very individualized and depends on the sensitivity of the uterus, which is determined by the oxytocin receptor concentration. However, the physician should be aware of the fact that oxytocin even in its pure form has inherent pressor and antidiuretic properties which may become manifest when large doses are administered. These properties are thought to be due to the fact that oxytocin and vasopressin differ in regard to only two of the eight amino acids (see PRECAUTIONS section). 

Oxytocin is distributed throughout the extracellular fluid. Small amounts of the drug probably reach the fetal circulation. Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation. Following intravenous administration of oxytocin, uterine response occurs almost immediately and subsides within 1 hour. Following intramuscular injection of the drug, uterine response occurs within 3 to 5 minutes and persists for 2 to 3 hours. Its rapid removal from plasma is accomplished largely by the kidney and the liver. Only small amounts are excreted in urine unchanged.
Analogous to intervention group II, patients in this group are invited to the study center after verbal and written information. These patients will attend the one-off evaluation examination at the study center 36 months after the operation.
In placebo-controlled, double-blind, and open-label clinical studies, 1483 adults and children 12 years and older received treatment with triamcinolone acetonide nasal spray. These patients were treated for an average duration of 51 days. In the controlled trials (2-5 weeks duration) from which the following adverse reaction data are derived, 1394 patients were treated with triamcinolone acetonide nasal spray for an average of 19 days. In a long-term, open-label study, 172 patients received treatment for an average duration of 286 days. Adverse reactions from 12 studies in adults and adolescent patients 12 to 17 years of age receiving triamcinolone acetonide nasal spray 27.5 mcg to 440 mcg once daily are summarized in Table 1.

In clinical trials, nasal septum perforation was reported in one adult patient who received triamcinolone acetonide nasal spray.

A total of 602 children 6 to 12 years of age were studied in 3 double-blind, placebo-controlled clinical trials. Of these, 172 received 110 mcg/day and 207 received 220 mcg/day of triamcinolone acetonide nasal spray for two, six, or twelve weeks. The longest average durations of treatment for patients receiving 110 mcg/day and 220 mcg/day were 76 days and 80 days, respectively. One percent of patients treated with triamcinolone acetonide were discontinued due to adverse experiences. No patient receiving 110 mcg/day and one patient receiving 220 mcg/day discontinued due to a serious adverse event. A similar adverse reaction profile was observed in pediatric patients 6 to 12 years of age as compared to adolescents and adults with the exception of epistaxis which occurred in less than 2% of the children studied. Adverse reactions from 2 studies in children 4 to 12 years of age receiving triamcinolone acetonide nasal spray 110 mcg once daily are summarized in Table 2.

Labeling describing adverse events of triamcinolone acetonide nasal spray in pediatric patients 2 to 5 years of age is approved for Sanofi-Aventis U.S. Inc.’s Nasacort® AQ Nasal Spray. However, due to Sanofi-Aventis U.S. Inc.’s marketing exclusivity rights, a description of those adverse events is not approved for this triamcinolone acetonide nasal spray labeling.

In the event of accidental overdose, an increased potential for these adverse experiences may be expected, but acute systemic adverse experiences are unlikely. [see Overdosage (10)]
PURPOSE:To obtain an antiallergic and an antiinflammatory agents, containing an extract of Corydalis bulbosa C. ternata as an active ingredient and orally administrable with hardly any side effects. CONSTITUTION:This antiallergic agent contains an extract prepared by extracting a tuber, etc., of Corydalis bulbosa C. ternata which is a perennial herb naturally growing in the eastern part of China with one or two or more polar solvents, e.g. an alcohol such as methanol or ethanol, water, ether or chloroform in combination as an active ingredient. The extract of the Corydalis bulbosa C. ternata is directly administered or prepared into a pharmaceutical preparation such as an oral agent, e.g. a tablet, a capsule, a granule, a powder or a solution or a parenteral agent, e.g. an parenteral injection, an external preparation, a suppository, an inhalant, a nasal drop or an eye drop and administered. The agent is useful for treating allergic rhinitis, allergic conjunctivitis, eczematous dermatitis, urticaria, conjunctivitis, bronchial asthma, chronic articular rheumatism, etc.
A traditional Chinese medicine composition for treating dysmenorrhea, a dysmenorrhea patch and a preparation method thereof belong to the technical field of traditional Chinese medicine compositions and traditional Chinese medicine products. The traditional Chinese medicine composition for treating dysmenorrhea is prepared from 5-50 parts of clove; 2-30 parts of cinnamon; 2-35 parts of fennel; 1-25 parts of safflower and 3-35 parts of long pepper. The Chinese medicinal composition can be made into dysmenorrhea patch, and is additionally provided with a bottle of additive solution for promoting drug absorption, wherein the additive solution comprises succus Zingiberis recens and yellow wine. The prepared dysmenorrheal patch is provided with a heating bag, on one hand, the patch can play a role in warming treatment, on the other hand, pores of skin relax after heating, and drug absorption is promoted under the action of the additive solution. The ginger juice in the additive solution has the functions of warming channel and dispelling cold, and the yellow wine can not only promote the absorption of water-soluble medicines, but also can be used as a solvent to promote the dissolution and absorption of fat-soluble components. The preparation process is simple, the product is convenient to carry and use, the raw materials are all medicinal and edible traditional Chinese medicines, and the product has no other additives, no pollution and safe use.
Goal setting will be performed by the patient together with the physician according to the SMART principle (specific, measureable, achievable, realistic, time bound). The goals will be classified according to the International Classification of Functioning, Disability and Health. Goal attainment will be assessed using the Goal Attainment Scale - Light. Comprehensive assessment of motor functioning will address range of motion, spasticity, pain, degree of motor disability and degree of dependence in daily activities. The prescribed exercises for the test group will be passive or active, depending on spasticity of the impaired upper limb. Both groups will keep an Exercise Diary during the second part of the study.
The intervention is comprised of two components to link randomized patients to our health system childcare facility: 1) navigation by the research assistant to the childcare facility and 2) placement of the facility EMR referral. Navigation will occur an eligible patient is randomized to the intervention group. Navigation will consist of the research assistant educating the patient about the childcare facility and providing information about how to access the childcare facility during the telephone contact and via mailed written materials.